SpringWorks Therapeutics Surges to 11th in Trading Volume as Merck KGaA Announces $3.9 Billion Acquisition

On April 28, 2025, SpringWorks Therapeutics (SWTX) experienced a significant surge in trading volume, with a turnover of $36.81 billion, marking a 957.9% increase from the previous day. This substantial rise placed SpringWorks at the 11th position in terms of trading volume for the day. The stock price of SpringWorks also saw a notable increase, rising by 3.26%.

Merck KGaA, a leading science and technology company based in Darmstadt, Germany, has announced its acquisition of SpringWorks Therapeutics. This strategic move aims to accelerate the sustainable growth of Merck's healthcare business. The acquisition, valued at $3.9 billion, includes a purchase price of $47 per share in cash. This deal represents a significant step in Merck's portfolio strategy, positioning the company as a globally diversified innovation and technology powerhouse. The acquisition is expected to immediately contribute to Merck's revenues and is projected to be accretive to Merck's earnings per share in 2027.

SpringWorks Therapeutics is a U.S. biopharmaceutical company known for its first-in-class, systemic standard-of-care therapy for adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. The acquisition will strengthen Merck's presence in the United States and expand the reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including approval from SpringWorks' shareholders and required regulatory approvals.